Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Brian Loper is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 5 original sources on average, compared with 4.1 for the broader beat in this window.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Brian Loper is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 5 original sources on average, compared with 4.1 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6 in the same window. BioLargo, Inc. appears in 1 tracked Healthcare story from March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BioLargo, Inc.. Shared-story counts are live from our verified record — not editorial picks.
REGENXBIO and BioLargo reported Q4 2025 results marked by wider-than-expected losses, reflecting a challenging environment for high-growth biotech and environmental health firms. As REGENXBIO navigates the costly gene therapy pipeline, the broader market trend shows a tightening of fiscal performance across specialized technology sectors.
Source: Insider Trading · Insider Trading
BioLargo, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
